AB Science: European patent granted for masitinib
This new European patent protects masitinib's intellectual property in this indication until October 2036, and adds to the
intellectual property coverage already granted in the United States and Japan.
Masitinib is positioned in the treatment of patients with severely symptomatic systemic mastocytosis.
Masitinib has also been granted orphan drug status for mastocytosis by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
This orphan drug status confers market exclusivity for 10 and 7 years in Europe and the United States respectively, following product registration.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction